Privium Fund Management B.V. Has $733,000 Stock Position in 4D Molecular Therapeutics, Inc. $FDMT

Key Points

• Privium Fund Management B.V. increased its stake in 4D Molecular Therapeutics, Inc. by 50.7% during the 2nd quarter, now holding approximately $733,000 worth of 197,458 shares.
• Several large investors have also raised their positions in FDMT, with BVF Inc. increasing its holdings by 70.8% to over $14 million.
• Analysts have mixed ratings on 4D Molecular Therapeutics, with a consensus rating of "Moderate Buy" and an average price target of $30.40, despite recent earnings showing a larger-than-expected loss.

Privium Fund Management B.V. raised its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 50.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,458 shares of the company's stock after acquiring an additional 66,458 shares during the quarter. Privium Fund Management B.V. owned about 0.43% of 4D Molecular Therapeutics worth $733,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of FDMT. BVF Inc. IL increased its holdings in shares of 4D Molecular Therapeutics by 70.8% in the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock valued at $14,733,000 after purchasing an additional 1,890,647 shares in the last quarter. Federated Hermes Inc. boosted its position in 4D Molecular Therapeutics by 33,131.8% in the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock valued at $4,038,000 after buying an additional 1,246,419 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of 4D Molecular Therapeutics by 1,103.4% in the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock valued at $1,290,000 after buying an additional 367,317 shares during the period. Millennium Management LLC raised its position in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock worth $5,278,000 after acquiring an additional 213,264 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of 4D Molecular Therapeutics during the first quarter valued at $486,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Roth Capital lowered their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Chardan Capital reiterated a "buy" rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $30.40.

4D Molecular Therapeutics Trading Up 14.5%

Shares of FDMT opened at $11.27 on Tuesday. The stock has a market cap of $526.31 million, a P/E ratio of -3.19 and a beta of 2.93. 4D Molecular Therapeutics, Inc. has a 1 year low of $2.23 and a 1 year high of $11.29. The stock's 50-day moving average price is $7.68 and its two-hundred day moving average price is $5.22.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. As a group, equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.